DDInter1042 DDInter1756
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.
Telavancin {u} (Compound) resembles {v} (Compound) Oritavancin
Telavancin {u} (Compound) resembles {v} (Compound) Vancomycin
Telavancin {u} (Compound) is included by {v} (Pharmacologic Class) Lipoglycopeptides
Telavancin {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Telavancin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Telavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Castor oil
Telavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Telavancin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Telavancin {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Telavancin (Compound) resembles Oritavancin (Compound)
Telavancin (Compound) resembles Vancomycin (Compound)
Telavancin (Compound) is included by Lipoglycopeptides (Pharmacologic Class)
Telavancin (Compound) causes Abdominal discomfort (Side Effect)
Telavancin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Telavancin may lead to a major life threatening interaction when taken with Vemurafenib
Telavancin may lead to a major life threatening interaction when taken with Dolasetron